J Cancer 2016; 7(6):650-655. doi:10.7150/jca.13460 This issue Cite

Review

miR-196, an Emerging Cancer Biomarker for Digestive Tract Cancers

Ya-Ching Lu1*, Joseph T Chang2*, Err-Cheng Chan1, Yin-Kai Chao3, Ta-Sen Yeh4, Jinn-Shiun Chen5, Ann-Joy Cheng1✉

1. Department of Medical Biotechnology and Laboratory science, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan;
2. Department of Radiation Oncology, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan;
3. Department of Thoracic Surgery, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan;
4. Department of General Surgery, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan;
5. Department of Colorectal Surgery, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan.
*First and second authors contributed equally.

Citation:
Lu YC, Chang JT, Chan EC, Chao YK, Yeh TS, Chen JS, Cheng AJ. miR-196, an Emerging Cancer Biomarker for Digestive Tract Cancers. J Cancer 2016; 7(6):650-655. doi:10.7150/jca.13460. https://www.jcancer.org/v07p0650.htm
Other styles

File import instruction

Abstract

Over the past decade, the emergence of microRNA (miRNA) research has firmly established this molecular family as a key component in cells. MiRNAs, which function as negative gene regulators, participate in multiple biological processes and maintain homeostasis in cells. The dysregulation of miRNA may contribute to numerous human disorders, including cancer. Recently, miR-196 was found to be aberrantly expressed in a wide range of malignant diseases, which suggests that it plays important roles in carcinogenesis. Here, we summarize the current knowledge concerning miR-196 family in cancers. This review includes miR-196 gene structure and aberrant expression in various cancers, and current understanding of numerous functions and regulatory targets of miR-196 in specific cancers. Since miR-196 are consistently found over-expressed in digestive tract cancer tissues, we also reviewed the clinical significance and potential applications of miR-196 in these cancers. We highlight that miR-196 may serve as an emerging cancer biomarker for digestive tract cancers.

Keywords: miR-196, cancer, clinical application, regulatory mechanism.


Citation styles

APA
Lu, Y.C., Chang, J.T., Chan, E.C., Chao, Y.K., Yeh, T.S., Chen, J.S., Cheng, A.J. (2016). miR-196, an Emerging Cancer Biomarker for Digestive Tract Cancers. Journal of Cancer, 7(6), 650-655. https://doi.org/10.7150/jca.13460.

ACS
Lu, Y.C.; Chang, J.T.; Chan, E.C.; Chao, Y.K.; Yeh, T.S.; Chen, J.S.; Cheng, A.J. miR-196, an Emerging Cancer Biomarker for Digestive Tract Cancers. J. Cancer 2016, 7 (6), 650-655. DOI: 10.7150/jca.13460.

NLM
Lu YC, Chang JT, Chan EC, Chao YK, Yeh TS, Chen JS, Cheng AJ. miR-196, an Emerging Cancer Biomarker for Digestive Tract Cancers. J Cancer 2016; 7(6):650-655. doi:10.7150/jca.13460. https://www.jcancer.org/v07p0650.htm

CSE
Lu YC, Chang JT, Chan EC, Chao YK, Yeh TS, Chen JS, Cheng AJ. 2016. miR-196, an Emerging Cancer Biomarker for Digestive Tract Cancers. J Cancer. 7(6):650-655.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Popup Image